Inovio Pharmaceuticals Return on Equity

Inovio Pharmaceuticals posts a ROE of 250367.48%. That is above the Industrials sector average of 35.28%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Industrials stocks, a ROE near 35.28% is typical. Inovio Pharmaceuticals's 250367.48% is higher that level. That is roughly 709615.4% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Inovio Pharmaceuticals's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 250367.48%; use YoY and peer views to separate noise from signal.

Context for INO's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 35.28%), and (3) consistency with growth and profitability. This page covers the first two; Inovio Pharmaceuticals's other metric pages and overview cover the third.

Judging Inovio Pharmaceuticals against Industrials peers is usually better than using a market-wide rule of thumb. Business models inside Industrials are more comparable, which makes gaps in ROE easier to interpret. Start with 250367.48% here, then scan peer and history charts to see if the gap is persistent.